Yarrow Bioscience, Inc.
YARWYarrow Bioscience, Inc. in brief
Yarrow Bioscience, Inc. is a listed company in the Biotechnology industry, based in California, USA. It was founded in 2011. Its market value was $307 M on 28 October 2026, which makes it the 14,688th largest listed company in the world and the 2,862nd largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $26 M. It employs about 10 people. Its largest product and service lines by sales in 2025 were Royalty revenues (95%). Its shares trade under the symbol YARW (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Yarrow Bioscience, Inc.
We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need.
We have exclusive worldwide rights to research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain inhibitors for the treatment of any disease, disorder or condition in humans, which we licensed from Tay Therapeutics Ltd., formerly known as In4Derm Ltd. BET proteins are epigenetic enablers of transcription that regulate the expression of specific genes. Each BET protein consists of two bromodomains and one end terminal domain. Through our transaction with Tay, we obtained access to a library of new small molecule BET inhibitor compounds including those that inhibit both BD1 and BD2 and that selectively inhibit BD2. We initially focused our development efforts with these molecules on immune-mediated inflammatory diseases, which are not being targeted by current BET inhibitors in development.
Yarrow Bioscience, Inc. timeline
- 2011
- 🏁· approximateFounded
- 2013
- ✎Renamed Menlo Therapeutics, Inc.Formerly Tigercat Pharma, Inc..
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as Menlo Therapeutics, Inc.Final prospectus filed with the SEC on 26 January 2018; shares registered for exchange trading on 19 January 2018.
- 2020
- 💰Record revenue of $21 millionFY2020, the highest of the 8 years on record.
- ✎Renamed VYNE Therapeutics Inc.Formerly Menlo Therapeutics, Inc..
- 2026
- ✎Renamed Yarrow Bioscience, Inc.Formerly VYNE Therapeutics Inc..
Events of Yarrow Bioscience, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,921 (Oct 2026) · #2,866 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 625.6×
- Price / book
- 11.0×
- Free cash flow yield
- -10.8%
- Net margin (TTM)
- -3816.3%
- Operating margin
- -5219.3%
- Return on equity
- -67.4%
- Liabilities / assets
- 8.0%
- Net debt
- $-24M
- Revenue growth
- +14.0%
- R&D / revenue
- 3375.4%
- Revenue per employee
- $57 K
- Profit per employee
- $-2.6 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | +14.0% | $-30M | $-26M | -4645.6% |
| Dec 2024 | $1M | +19.0% | $-44M | $-40M | -7966.0% |
| Dec 2023 | $0M | -12.5% | $-29M | $-28M | -6773.8% |
| Dec 2022 | $0M | -48.4% | $-34M | $-23M | -4835.4% |
| Dec 2021 | $1M | -95.6% | $-39M | $-73M | -7884.9% |
| Dec 2020 | $21M | +4670.5% | $-253M | $-256M | -1217.6% |
| Dec 2019 | $0M | -95.9% | $-96M | $-95M | -21631.8% |
| Dec 2018 | $11M | — | $-75M | $-74M | -697.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-33M | $0M | $-33M | $-0.62 | — |
| Dec 2024 | $-34M | $0M | $-34M | $-0.93 | — |
| Dec 2023 | $-25M | $0M | $-25M | $-2.78 | — |
| Dec 2022 | $-29M | — | — | $-7.28 | — |
| Dec 2021 | $-56M | $0M | $-56M | $-25.64 | — |
| Dec 2020 | $-137M | $0M | $-137M | $7.88 | — |
| Dec 2019 | $-73M | $1M | $-74M | $11.22 | — |
| Dec 2018 | $-69M | $1M | $-69M | $11.47 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-10M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 14, 20268-KCurrent reportMaterial agreement
- Sep 10, 20268-KCurrent reportOther events
- Aug 13, 20268-K/ACurrent report (amended)Results of operations · Regulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 30, 20268-KCurrent reportOther events
- Jul 28, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Results of operations · Unregistered share sale · Change in control · Directors or officers changed · Bylaws amended · Regulation FD disclosure
- Jul 21, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jul 20, 20268-KCurrent reportShareholder vote
- Jul 14, 20268-KCurrent reportRegulation FD disclosure
- Jul 10, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 21, 20268-KCurrent reportRegulation FD disclosure
Official filings of Yarrow Bioscience, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-30 M
- Net income
- $-26 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $30 M
- Total liabilities
- $2 M
- Total equity
- $28 M
As of December-2025
Top 49 institutional investors in Yarrow Bioscience, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Logos Global Management LP | 1,026,258 | New | 6.74% | $23 M | Nov 16, 2026 |
| 2 | Bellevue Group AG | 1,000,000 | New | 6.56% | $23 M | Nov 16, 2026 |
| 3 | Perceptive Advisors LLC | 813,098 | New | 5.34% | $18 M | Nov 16, 2026 |
| 4 | Ameriprise Financial Inc | 739,538 | New | 4.85% | $17 M | Nov 16, 2026 |
| 5 | Siren, L.L.C. | 675,000 | New | 4.43% | $15 M | Nov 12, 2026 |
| 6 | Spruce Street Capital LP | 607,382 | New | 3.99% | $14 M | Nov 13, 2026 |
| 7 | venBio Partners LLC | 554,769 | New | 3.64% | $12 M | Nov 16, 2026 |
| 8 | Soleus Capital Management, L.P. | 416,993 | New | 2.74% | $9 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 368,034 | New | 2.42% | $8 M | Nov 13, 2026 |
| 10 | Braidwell LP | 331,400 | New | 2.18% | $7 M | Nov 16, 2026 |
| 11 | Driehaus Capital Management LLC | 305,000 | New | 2.00% | $7 M | Nov 16, 2026 |
| 12 | Silverarc Capital Management, LLC | 301,919 | New | 1.98% | $7 M | Nov 12, 2026 |
| 13 | Citadel Advisors LLC | 297,361 | New | 1.95% | $7 M | Nov 16, 2026 |
| 14 | Janus Henderson Group Ltd. | 283,341 | — | 1.86% | $6 M | Nov 16, 2026 |
| 15 | ADAR1 Capital Management, LLC | 282,996 | New | 1.86% | $6 M | Nov 16, 2026 |
| 16 | Orbimed Advisors LLC | 266,306 | New | 1.75% | $6 M | Nov 16, 2026 |
| 17 | Marshall Wace, LLP | 237,183 | New | 1.56% | $5 M | Nov 13, 2026 |
| 18 | Squadron Capital Management LLC | 225,000 | New | 1.48% | $5 M | Nov 16, 2026 |
| 19 | BlackRock, Inc. | 89,892 | New | 0.59% | $2 M | Nov 13, 2026 |
| 20 | Geode Capital Management, LLC | 84,720 | New | 0.56% | $2 M | Nov 6, 2026 |
| 21 | Morgan Stanley | 68,094 | New | 0.45% | $2 M | Nov 13, 2026 |
| 22 | J. Goldman & Co LP | 55,751 | New | 0.37% | $1 M | Nov 16, 2026 |
| 23 | Vanguard Fiduciary Trust Co | 50,629 | New | 0.33% | $1 M | Nov 13, 2026 |
| 24 | Monashee Investment Management LLC | 40,000 | New | 0.26% | $1 M | Nov 6, 2026 |
| 25 | Seven Fleet Capital Management LP | 40,000 | New | 0.26% | $1 M | Nov 16, 2026 |
Show all 49: investors 26 to 49
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nantahala Capital Management, LLC | 39,198 | New | 0.26% | $1 M | Nov 13, 2026 |
| 27 | Walleye Capital LLC | 33,265 | New | 0.22% | $1 M | Nov 13, 2026 |
| 28 | Qube Research & Technologies Ltd | 23,954 | New | 0.16% | $1 M | Nov 13, 2026 |
| 29 | Two Sigma Investments, LP | 23,811 | New | 0.16% | $1 M | Nov 16, 2026 |
| 30 | Lynx1 Capital Management LP | 22,000 | New | 0.14% | $0 M | Nov 16, 2026 |
| 31 | Northern Trust Corp | 18,164 | New | 0.12% | $0 M | Nov 16, 2026 |
| 32 | Prelude Capital Management, LLC | 16,975 | New | 0.11% | $0 M | Nov 16, 2026 |
| 33 | XTX Topco Ltd | 12,282 | New | 0.08% | $0 M | Nov 16, 2026 |
| 34 | Soros Fund Management LLC | 12,000 | New | 0.08% | $0 M | Nov 13, 2026 |
| 35 | Millennium Management LLC | 10,785 | New | 0.07% | $0 M | Nov 16, 2026 |
| 36 | Atom Investors LP | 10,206 | New | 0.07% | $0 M | Nov 16, 2026 |
| 37 | KVP Capital Advisors, LP | 10,011 | New | 0.07% | $0 M | Nov 16, 2026 |
| 38 | Jump Financial, LLC | 9,439 | New | 0.06% | $0 M | Nov 13, 2026 |
| 39 | US Bancorp \de\ | 4,992 | New | 0.03% | $0 M | Nov 5, 2026 |
| 40 | Aster Capital Management (DIFC) Ltd | 3,179 | New | 0.02% | $0 M | Nov 12, 2026 |
| 41 | Persistent Asset Partners Ltd | 3,092 | New | 0.02% | $0 M | Nov 13, 2026 |
| 42 | Vanguard Global Advisers, LLC | 3,081 | New | 0.02% | $0 M | Nov 13, 2026 |
| 43 | Tower Research Capital LLC (TRC) | 2,076 | New | 0.01% | $0 M | Nov 16, 2026 |
| 44 | UBS Group AG | 1,744 | New | 0.01% | $0 M | Nov 10, 2026 |
| 45 | Citigroup Inc | 232 | New | 0.00% | $0 M | Nov 4, 2026 |
| 46 | Caitong International Asset Management Co., Ltd | 28 | New | 0.00% | $0 M | Oct 29, 2026 |
| 47 | MB, Levis & Associates, LLC | 20 | New | 0.00% | $0 M | Oct 16, 2026 |
| 48 | Centerpoint Advisors, LLC | 12 | New | 0.00% | $0 M | Nov 5, 2026 |
| 49 | Hurley Capital, LLC | 11 | New | 0.00% | $0 M | Nov 5, 2026 |
Superinvestors holding Yarrow Bioscience, Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Soros Fund Management · Soros Fund Management$0 Mnew · Sep 30, 2026
Insider trading at Yarrow Bioscience, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Roderick Wong10% owner | Otherindirect | -133,290 | — | — | 266,307 | Form 4 |
| filed | David DomzalskiPRESIDENT AND CEO, Director | Shares withheld for tax | -79,391 | $0.900 | $71 K | 347,174 | Form 4 |
| filed | Tyler ZerondaCHIEF FINANCIAL OFFICER | Shares withheld for tax | -22,516 | $0.900 | $20 K | 74,918 | Form 4 |
| filed | Iain StuartCHIEF SCIENTIFIC OFFICER | Shares withheld for tax | -15,405 | $0.900 | $14 K | 95,944 | Form 4 |
| filed | Mutya HarschCHIEF LEGAL OFFICER AND GC | Shares withheld for tax | -22,516 | $0.900 | $20 K | 95,918 | Form 4 |
| filed | David DomzalskiPRESIDENT AND CEO, Director | Shares withheld for tax | -12,214 | $0.650 | $8 K | 426,565 | Form 4 |
| filed | Mutya HarschCHIEF LEGAL OFFICER AND GC | Shares withheld for tax | -3,464 | $0.650 | $2 K | 118,434 | Form 4 |
| filed | Iain StuartCHIEF SCIENTIFIC OFFICER | Shares withheld for tax | -2,370 | $0.650 | $2 K | 111,349 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Yarrow Bioscience, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-50 reverse split ; 1-for-18.02 reverse split ; 1-for-4 reverse split
Fails to deliver
- : 2 shares at $20.12
- : 5,214 shares at $18.31
- : 10,148 shares at $18.60
- : 10,180 shares at $19.82
- : 327 shares at $24.00
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Yarrow Bioscience, Inc. scorecard#
Passes 6 of the 17 checks that could be worked out: strongest in financial health (4 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median11.0×Price to book 11.0× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median625.6×Price to sales 625.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-10.8%Free cash flow is -10.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.62 vs -0.93Diluted EPS -0.62 in fiscal 2025 against -0.93 the year before (report's currency).
- ✓Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$256 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-66.3%-66.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health4 of 5
- ✓Short-term assets cover short-term liabilities12.5×Current ratio 12.50 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $24 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone39.33Z-score 39.33 (safe zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.4%Diluted shares up 0.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Yarrow Bioscience, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.6+13.8%100% | 0.5+18.2%100% | 0.4−11.1%100% | 0.5−48.8%100% | 0.9r15−95.6%100% | 21+4639%100% | 0.4r0−95.8%100% | 11+132%100% | 4.6+580%100% | 0.7—100% | |
| Cost of revenue | — | — | — | — | 3.3+141%360% | 1.4—6.6% | 0—0.0% | 0—0.0% | — | — | |
| Research and development | 19−37.8%3375% | 31+89.8%6177% | 16−11.3%3846% | 18−5.9%3854% | 20r25−55.1%2099% | 44−15.0%207% | 51r54−20.6%11558% | 64r53+122%606% | 29+158%633% | 11—1670% | |
| Selling, general and administrative | — | — | — | 16−19.3%3435% | 20r54−77.3%2180% | 90+98.5%427% | 45+222%10184% | 14—132% | — | — | |
| General and administrative | 11−16.0%1944% | 13−1.4%2633% | 13−18.4%3154% | 16—3435% | — | — | 22+84.5%5075% | 12+136%115% | 5.2+37.8%113% | 3.8—557% | |
| Operating expenses | — | — | — | — | — | — | 76+17.0%17210% | 65+90.7%613% | 34+128%746% | 15—2226% | |
| Total costs and expenses | 30−31.3%5319% | 44+48.7%8810% | 30−14.6%7000% | 35−12.7%7290% | 40r79−85.4%4279% | 272+183%1296% | 96+22.7%21742% | 78—738% | — | — | |
| Operating income | −30—−5219% | −44—−8710% | −29—−6900% | −34—−7190% | −39r−68—−4179% | −253—−1203% | −96r−76—−21642% | −75r−55—−704% | −30—−646% | −14—−2126% | |
| Interest expense and finance costs | — | — | — | 0−100%0.0% | 5.6+27.8%603% | 4.4+377%20.9% | 0.9—208% | 0—0.0% | — | — | |
| Other non-operating income (expense) | 3.0−21.3%529% | 3.8+177%765% | 1.4+282%327% | 0.4—76.1% | −0.1−112%−14.5% | 1.1r−1.1—5.3% | −1.4r2.5—−325% | −0.9r3.1−282%−8.8% | 0.5+95.8%11.3% | 0.3—39.2% | |
| Income before tax | −27—−4690% | −40—−7945% | −28—−6574% | −34—−7114% | −45r−74—−4797% | −256—−1219% | −95—−21525% | −74—−695% | — | — | |
| Income tax | 0.00.0%0.7% | 0.0—0.8% | 0−100%0.0% | 0.0—2.7% | −0.4—−48.1% | −0.3—−1.2% | −0.2r0−183%−39.7% | 0.2r0—2.0% | 0—0.0% | — | |
| Income from continuing operations | −27—−4691% | −40—−7946% | −28—−6574% | −34—−7116% | −44—−4748% | — | — | — | — | — | |
| Income from discontinued operations | 0.3—44.4% | −0.0—−5.4% | −0.6−105%−137% | 11—2251% | −29—−3128% | — | — | — | — | — | |
| Net income attributable to shareholders | −26—−4646% | −40—−7951% | −28—−6710% | −23—−4866% | −73—−7876% | −256—−1217% | −95r−74—−21485% | −74r−51—−697% | −29—−635% | −14—−2087% | |
| Earnings per share, basic | -0.62—— | -0.93—— | -2.78—— | -7.28—— | -25.64r1.42−425%— | 7.88−29.8%— | 11.22r-3.09−2.2%— | 11.47r-2.37—— | -5.69—— | -2.82—— | |
| Earnings per share, diluted | -0.62—— | -0.93—— | -2.78—— | -7.28—— | -25.64r1.42−425%— | 7.88−29.8%— | 11.22r-3.09−2.2%— | 11.47r-2.37—— | -5.69—— | -2.82—— | |
| Shares, weighted average (basic) | 43+0.4%— | 43+315%— | 10+222%— | 3.2+11.4%— | 2.9r51−91.2%— | 32—— | — | — | — | — | |
| Shares, weighted average (diluted) | 43+0.4%— | 43+315%— | 10+222%— | 3.2+11.4%— | 2.9r51−91.2%— | 32+282%— | 8.5r24+31.2%— | 6.5r22+26.6%— | 5.1+2.4%— | 5.0—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 100r24+402%99.6% | 20−34.9%29.8% | 31−0.9%31.3% | 31−26.8%75.8% | 42−26.6%63.0% | 58+31.5%61.4% | 44r31+57.0%53.9% | 28r50+173%19.9% | 10+153%15.3% | 4.0r4.0—9.6% | |
| Short-term investments | 5.0−88.0%5.0% | 42−33.6%62.2% | 63—64.1% | 0—0.0% | 0−100%0.0% | 1.0−93.8%1.1% | 17r46−80.8%20.6% | 87+76.0%62.0% | 49+83.4%73.7% | 27—63.9% | |
| Receivables | — | — | — | 0.2−97.7%0.4% | 7.6−52.1%11.3% | 16+11618%16.9% | 0.1—0.2% | — | 0.8—1.2% | 0—0.0% | |
| Inventory | — | — | — | — | 7.3−1.5%10.9% | 7.4+446%7.9% | 1.4—1.7% | — | — | — | |
| Other current assets | 0.0r1.0−99.8%0.0% | 2.9+10.0%4.4% | 2.7+15.5%2.7% | 2.3r2.1−49.6%5.6% | 4.6r5.1−0.6%6.8% | 4.6+195%4.9% | 1.6r1.4−52.1%1.9% | 3.3−9.1%2.3% | 3.6+466%5.3% | 0.6—1.5% | |
| Current assets | 100r30+55.2%99.6% | 64−32.9%96.3% | 96+151%98.2% | 38−39.4%93.9% | 63−27.6%94.2% | 87+14.2%93.1% | 76r78−45.2%94.2% | 140+118%99.7% | 64+102%95.5% | 32—75.0% | |
| Property, plant and equipment | 0r0.1−100%0.0% | 0.1—0.2% | 0—0.0% | 0−100%0.0% | 0.4−36.2%0.5% | 0.6−80.8%0.6% | 2.9r0.1+1876%3.6% | 0.1+421%0.1% | 0.0+3.7%0.0% | 0.0—0.1% | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.1−55.1%0.1% | 0.2—0.2% | 0—0.0% | 0−100%0.0% | 1.6−6.6%1.7% | 1.7r0.7—2.1% | — | — | — | |
| Long-term investments | — | — | — | — | — | — | — | — | 3.0−71.4%4.5% | 10—24.8% | |
| Non-current assets | 0.4r0.2−83.5%0.4% | 2.5+43.3%3.7% | 1.7−30.6%1.8% | 2.5−35.7%6.1% | 3.9−40.5%5.8% | 6.5+36.6%6.9% | 4.7—5.8% | — | — | — | |
| Total assets | 100r30+50.1%100% | 67−31.5%100% | 98+140%100% | 41−39.2%100% | 67−28.5%100% | 94+15.5%100% | 81r79−42.0%100% | 140+109%100% | 67+59.0%100% | 42—100% | |
| Accounts payable | 1.5r1.0−43.3%1.5% | 2.7+63.2%4.0% | 1.7−30.5%1.7% | 2.4−63.3%5.9% | 6.5+36.2%9.7% | 4.8+26.8%5.1% | 3.8+14.6%4.6% | 3.3+33.6%2.4% | 2.5+61.3%3.7% | 1.5—3.6% | |
| Debt due within a year | — | — | — | — | — | 0—0.0% | — | — | — | — | |
| Current liabilities | 72r2.4+383%71.3% | 15+96.6%22.1% | 7.5−19.3%7.7% | 9.3−49.2%22.9% | 18−15.4%27.5% | 22r21−25.8%23.2% | 29r11+207%36.1% | 9.5+22.1%6.8% | 7.8+100%11.7% | 3.9—9.3% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 33+1.4%35.4% | 33—40.3% | — | — | — | |
| Lease liabilities (non-current) | — | 0−100%0.0% | 0.1—0.1% | 0—0.0% | 0−100%0.0% | 0.9+30.6%0.9% | 0.7—0.8% | — | — | — | |
| Non-current liabilities | — | 0−100%0.0% | 1.4—1.4% | 0—0.0% | 0−100%0.0% | 34r35+0.7%36.8% | 34—42.2% | — | — | — | |
| Total liabilities | 72r2.4+383%71.3% | 15+65.6%22.1% | 9.0−4.2%9.2% | 9.3−49.2%22.9% | 18−67.3%27.5% | 56−11.5%60.0% | 64r11+566%78.3% | 9.6−34.5%6.8% | 15+16.7%21.8% | 12—29.7% | |
| Retained earnings | −71r−758—−70.7% | −731—−1093% | −691—−708% | −663—−1626% | −640—−954% | −566—−604% | −311r−184—−383% | −111—−79.1% | −59—−88.5% | −30—−71.6% | |
| Shareholders' equity | −71r28−236%−70.7% | 52−41.3%77.9% | 89+184%90.8% | 31−35.8%76.6% | 49+29.7%72.5% | 37+113%40.0% | 18r69−80.9%21.7% | 92r130+34.4%65.9% | 69r−57—103% | −29—−70.0% | |
| Total liabilities and equity | 100r30+50.1%100% | 67−31.5%100% | 98+140%100% | 41−39.2%100% | 67−28.5%100% | 94+15.5%100% | 81r79−42.0%100% | 140+109%100% | 67+59.0%100% | 42—100% | |
| Shares outstanding | 3.0r33−79.4%— | 15+5.2%— | 14+337%— | 3.2+8.5%— | 3.0r54−93.1%— | 43+374%— | 9.1r24−60.7%— | 23r23+338%— | 5.3+0.4%— | 5.3—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0+475%4.0% | 0.0—0.8% | 0−100%0.0% | 0.1−33.9%15.1% | 0.1−68.0%11.7% | 0.3−2.6%1.6% | 0.4+9.7%79.0% | 0.3—3.0% | — | — | |
| Share-based compensation | 2.3−30.1%405% | 3.3−0.1%659% | 3.3−23.1%779% | 4.3−46.8%901% | 8.1−55.4%868% | 18+270%86.2% | 4.9r6.7−8.0%1105% | 5.3r3.6+266%50.0% | 1.5+153%31.7% | 0.6—85.0% | |
| Cash from operating activities | −33—−5811% | −34—−6781% | −25—−5977% | −29—−6122% | −56—−6054% | −137—−653% | −73r−65—−16567% | −69r−53—−645% | −28r−28—−616% | −2.3r−2.3—−336% | |
| Capital expenditure | 0—0.0% | −0.1—−23.4% | 0—0.0% | — | 0—0.0% | −0.1—−0.5% | −1.1r−0.0—−239% | −0.6r−0.1—−5.3% | −0.0—−0.6% | −0.0—−4.6% | |
| Cash from investing activities | 37+59.9%6556% | 23—4664% | −57−466%−13527% | 16+1426%3284% | 1.0−98.8%110% | 89+113%424% | 42r41—9451% | −12r−34—−110% | −15r−15—−329% | −38r−37—−5566% | |
| Debt repaid | — | — | — | 0—0.0% | −36—−3913% | 0—0.0% | — | — | — | — | |
| Shares issued | — | — | — | 1.5−98.1%308% | 76+23.3%8161% | 62+349%294% | 14−85.0%3096% | 91—860% | — | — | |
| Cash from financing activities | −0.1—−25.1% | −0.1−100%−28.1% | 82+4885%19433% | 1.7−95.8%347% | 40−35.6%4273% | 62+28.9%294% | 48r5.0−48.1%10824% | 92r126+86.6%868% | 49—1080% | 0—0.0% | |
| Exchange-rate effect on cash | — | — | — | — | 0−100%0.0% | 0.0−97.6%0.0% | 0.0—9.3% | −0.0—−0.4% | — | — | |
| Change in cash | 4.1—719% | −11—−2145% | −0.3—−71.0% | — | — | — | −19−148%−4229% | 39+536%369% | 6.2—135% | −40—−5902% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | — | 0.1+40.6%100% | 0.1−57.4%100% | 0.1−65.2%100% | 0.2+106%100% | 0.1*+10.5%100% | 0.1+6.1%100% | 0.2+46.7%100% | 0.1—100% | 0.1*—100% | 0.1—100% | 0.1—100% | |
| Research and development | 5.3—— | 0.8−83.9%812% | 0.8−86.7%950% | 4.9−33.2%7074% | 6.1+65.2%3032% | 9.7*+220%11529% | 10+209%8469% | 7.3+1.0%3690% | 3.7—3784% | 3.0*—3978% | 3.3—2911% | 7.2—5358% | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | — | 3.0—2658% | 3.2—2385% | |
| General and administrative | 5.5—— | 2.4−11.7%2486% | 3.1−5.8%3587% | 2.7−17.0%3957% | 3.3−13.1%1621% | 3.2*−18.4%3774% | 3.0−2.2%2450% | 3.3+2.1%1661% | 3.8—3847% | 3.9*—5112% | 3.0—2658% | 3.2—2385% | |
| Total costs and expenses | 11—— | 3.2−58.0%3298% | 3.9−58.5%4537% | 7.6−28.2%11030% | 9.4+25.7%4653% | 13*+86.1%15302% | 13+108%10919% | 11+1.3%5351% | 7.5—7631% | 6.9*—9089% | 6.3—5568% | 10—7743% | |
| Operating income | −11—— | −3.1—−3198% | −3.8—−4437% | −7.5—−10930% | −9.2—−4553% | −13*—−15202% | −13—−10819% | −10—−5251% | −7.4—−7531% | −6.8*—−8989% | −6.2—−5468% | −10—−7643% | |
| Net interest income | 0.9—— | — | — | — | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 1.0—— | 0.2−88.7%209% | 0.2−61.1%269% | 1.8+79.3%2601% | 0.6−47.8%294% | 0.8*+11.8%905% | 0.9+473%772% | 1.0+258%506% | 1.1—1162% | 0.7*—895% | 0.2—143% | 0.3—207% | |
| Income before tax | — | −2.9—−2989% | −3.6—−4169% | −5.7—−8329% | −8.6—−4259% | −12*—−14298% | −12—−10047% | −9.4—−4745% | −6.2—−6368% | −6.2*—−8095% | −6.1—−5325% | −10—−7436% | |
| Income tax | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0.0*—4.8% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | — | −2.9—−2989% | −3.6—−4169% | −5.7—−8329% | −8.6—−4259% | −12*—−14302% | −12—−10047% | −9.4—−4745% | −6.2—−6368% | −6.2*—−8095% | −6.1—−5325% | −10—−7436% | |
| Income from discontinued operations | — | −0.1—−111% | 0—0.0% | −0.0—−11.6% | −0.0—−4.0% | −0.0*—−9.5% | 0—0.0% | −0.0—−5.6% | −0.0—−8.2% | −0.0*—−47.4% | −0.5—−450% | −0.0—−14.8% | |
| Net income attributable to shareholders | −9.7—— | −6.5r−3.0—−6713% | −2.7r−3.6—−3192% | −5.8—−8341% | −8.6—−4263% | −12*—−14312% | −12—−10047% | −9.4—−4751% | −6.2—−6377% | −6.2*—−8142% | −6.6—−5775% | −10—−7450% | |
| Earnings per share, basic | -0.43—— | -3.51—— | -0.08—— | -6.73r-0.13—— | -0.20—— | — | -0.29—— | -0.22—— | -0.15—— | — | -2.01—— | -3.09—— | |
| Earnings per share, diluted | -0.43—— | -3.51—— | -0.08—— | -6.73r-0.13—— | -0.20—— | — | -0.29—— | -0.22—— | -0.15—— | — | -2.01—— | -3.09—— | |
| Shares, weighted average (basic) | 23—— | 0.9+0.4%— | 43+0.2%— | 0.9r43−98.0%— | 43+0.2%— | — | 43+1198%— | 43+1201%— | 43—— | — | 3.3—— | 3.3—— | |
| Shares, weighted average (diluted) | 23—— | 0.9+0.4%— | 43+0.2%— | 0.9r43−98.0%— | 43+0.2%— | — | 43+1198%— | 43+1201%— | 43—— | — | 3.3—— | 3.3—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 269—98.1% | 23+4.0%97.1% | 25−12.7%95.2% | 22−25.5%49.3% | 28+48.0%50.0% | 20−34.9%29.8% | 16+5.3%21.4% | 30+43.5%34.2% | 19—20.8% | 31—31.3% | 15—80.2% | 21—82.7% | |
| Short-term investments | — | 0−100%0.0% | 0.3−98.7%1.1% | 18−63.7%39.4% | 22−67.0%39.1% | 42−33.6%62.2% | 54—70.8% | 48—56.0% | 67—73.0% | 63—64.1% | — | — | |
| Receivables | — | — | — | — | — | — | — | — | — | — | 0.3—1.3% | 0.2—0.9% | |
| Other current assets | 5.0—1.8% | 0.6−87.2%2.5% | 0.9−81.4%3.3% | 4.7−16.6%10.5% | 4.6+10.0%8.2% | 2.9+10.0%4.4% | 3.3+87.8%4.3% | 5.6+178%6.5% | 4.2—4.6% | 2.7—2.7% | 1.8—9.1% | 2.0—8.1% | |
| Current assets | 274—100.0% | 24−46.9%99.7% | 26−53.0%99.7% | 44−47.1%99.2% | 55−39.1%97.3% | 64−32.9%96.3% | 74+320%96.5% | 84+265%96.7% | 90—98.4% | 96—98.2% | 18—90.9% | 23—92.0% | |
| Property, plant and equipment | 0.1—0.0% | 0.1−23.5%0.3% | 0.1−21.5%0.3% | 0.1—0.2% | 0.1—0.2% | 0.1—0.2% | — | — | — | 0—0.0% | — | — | |
| Right-of-use (leased) assets | — | — | — | 0.0−78.8%0.1% | 0.1−65.6%0.1% | 0.1−55.1%0.1% | 0.1—0.2% | 0.2—0.2% | 0.2—0.2% | 0.2—0.2% | 0—0.0% | 0—0.0% | |
| Non-current assets | 0.1—0.0% | 0.1−79.2%0.3% | 0.1−94.4%0.3% | 0.4−86.9%0.8% | 1.5+3.9%2.7% | 2.5+43.3%3.7% | 2.7—3.5% | 2.9—3.3% | 1.5—1.6% | 1.7—1.8% | — | — | |
| Total assets | 274—100% | 24−47.2%100% | 26−54.1%100% | 45−48.4%100% | 56−38.5%100% | 67−31.5%100% | 76+295%100% | 87+247%100% | 92—100% | 98—100% | 19—100% | 25—100% | |
| Accounts payable | 2.1—0.8% | 0.6−56.6%2.6% | 0.3−92.6%1.0% | 1.4−68.7%3.2% | 3.5+26.4%6.3% | 2.7+63.2%4.0% | 4.0+457%5.2% | 4.5+290%5.2% | 2.8—3.0% | 1.7—1.7% | 0.7—3.7% | 1.2—4.6% | |
| Current liabilities | 6.5—2.4% | 1.5−73.6%6.5% | 1.2−89.9%4.8% | 5.8−50.3%13.1% | 12+77.4%21.8% | 15+96.6%22.1% | 13+96.3%16.6% | 12+84.4%13.6% | 6.9—7.6% | 7.5—7.7% | 6.4—33.5% | 6.4—25.5% | |
| Lease liabilities (non-current) | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0.0—0.0% | 0.1—0.1% | 0.1—0.1% | — | — | |
| Non-current liabilities | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0.0—0.0% | 1.4—1.5% | 1.4—1.4% | — | — | |
| Total liabilities | 6.5—2.4% | 1.5−73.6%6.5% | 1.2−89.9%4.8% | 5.8−50.5%13.1% | 12+48.0%21.8% | 15+65.6%22.1% | 13+63.1%16.6% | 12+53.2%13.6% | 8.3—9.1% | 9.0—9.2% | 7.8—40.3% | 7.7—30.8% | |
| Retained earnings | −90—−32.8% | −764—−3238% | −761—−2942% | −746—−1667% | −740—−1311% | −731—−1093% | −719—−944% | −707—−816% | −698—−761% | −691—−708% | −685—−3556% | −679—−2719% | |
| Shareholders' equity | 268—97.6% | −79r22−304%−337% | −73r25−266%−284% | 39−48.1%86.9% | 44r44−47.1%78.2% | 52−41.3%77.9% | 64+452%83.4% | 75+333%86.4% | 83—90.9% | 89—90.8% | 12—59.7% | 17—69.2% | |
| Total liabilities and equity | 274—100% | 24−47.2%100% | 26−54.1%100% | 45−48.4%100% | 56−38.5%100% | 67−31.5%100% | 76+295%100% | 87+247%100% | 92—100% | 98—100% | 19—100% | 25—100% | |
| Shares outstanding | 11—— | 0.7−96.6%— | 33+109%— | 20+36.0%— | 16+11.6%— | 15+5.2%— | 15+346%— | 15+343%— | 14—— | 14—— | 3.3—— | 3.3—— | |
| Cash-flow statement | |||||||||||||
| Depreciation and amortization | — | 0.0*0.0%6.2% | 0.00.0%7.0% | 0.0*—8.7% | 0.0—3.0% | — | — | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | |
| Share-based compensation | 0.7—— | 0.4−17.6%449% | 0.5−37.9%551% | 0.5−40.2%767% | 0.8−22.5%378% | 0.7*−1.5%832% | 0.7−14.9%607% | 0.9+1.0%447% | 1.0—1005% | 0.7*—934% | 0.9—757% | 0.9—649% | |
| Cash from operating activities | −90*—— | −2.0*—−2054% | −4.1—−4745% | −11*—−15657% | −11—−5674% | −9.0*—−10713% | −8.5*—−7033% | −8.5r−8.5*—−4284% | −8.0r−8.0—−8144% | −5.1*—−6759% | −5.2*—−4519% | −9.6*—−7092% | |
| Cash from investing activities | — | 0.3*−93.6%309% | 4.7−76.3%5465% | 4.7*−75.4%6775% | 20—9817% | 13*—15164% | −4.8*—−3987% | 19*—9606% | −3.6—−3642% | −62*—−82045% | 0*—0.0% | 0*—0.0% | |
| Shares issued | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0—0.0% | — | 0*—0.0% | 0*—0.0% | |
| Cash from financing activities | 265*—— | −0.0*—−14.4% | −0.0—−17.4% | −0.0*—−49.3% | −0.1—−43.1% | −0.1*−100%−157% | −0.0*—−1.7% | −0.0r−0.0*—−1.0% | −0.0r−0.0—−5.1% | 83*—108767% | −0.0*—−41.2% | −0.0*—−3.7% | |
| Change in cash | 170*—— | −1.7*—−1759% | 0.6−92.7%702% | −6.2*−158%−8930% | 8.3—4100% | 3.6*−76.2%4294% | −13*—−11021% | 11*—5321% | −12—−11791% | 15*—19963% | −5.2*—−4561% | −9.6*—−7096% | |
| Report | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Yarrow Bioscience, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Royalty revenues$1 M95%+14%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Yarrow Bioscience, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 4 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K/A | |
| Change in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changedResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Change in controlDirectors and officersMaterial agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Yarrow Bioscience, Inc. compares in Biotechnology
- Market cap$307 M · higher than 51% of 726
- Revenue$1 M · higher than 22% of 647
- Revenue growth14.0% · higher than 57% of 438
- Price / sales625.6× · lower than 1% of 339
- Price / book11.0× · lower than 14% of 534
- FCF yield-10.8% · higher than 55% of 449
- 🇺🇸 Benitec Biopharma Inc.$307 M
- 🇺🇸 Prelude Therapeutics Incorporated$311 M
- 🇰🇷 Prestige Biopharma Limited$311 M
- 🇩🇪 InflaRx N.V.$301 M
- 🇮🇪 Amarin Corporation$297 M
- 🇺🇸 Vogenx, Inc.$296 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Yarrow Bioscience, Inc.🇺🇸 | $307 M | — | — | +14.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Yarrow Bioscience, Inc.? Verify and update this profile — free
Show Yarrow Bioscience, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.